Immunovant (IMVT) PT Lowered to $33 at Stifel, 'We are buying'
- Dow hits milestone, S&P breaks record high on tech rally
- Thermo Fisher Scientific (TMO) to Acquire PPD, Inc. (PPD) for $47.50/sh, $17.4 Billion
- U.S. retail sales post largest gain in 10 months; weekly jobless claims fall
- Dell (DELL) Gains on Spin-Off of its 81% Stake in VMware (VMW), Analysts Bulled-Up as It Could Unlock $20 Per Share of Value for DELL
- The Stock Market is Almost 'Completely Broken' - Einhorn
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Stifel analyst Derek Archila lowered the price target on Immunovant (NASDAQ: IMVT) to $33.00 (from $54.00) while maintaining a Buy rating.
The analyst comments "We are buying this AMs weakness after IMVT announced it was pausing its clinical trials for IMVT-1401 in thyroid eye disease (TED) and warm autoimmune hemolytic anemia (WAIHA) after observing dose dependent LDL increases in patients from its Ph2 study in TED. Interestingly, increases have only been seen in TED patients, and our review of the literature suggests a few things: (1) it's likely this is TED specific given the biology - see below for details, but we don't think similar LDL increases will be seen in other indications outside TED; and (2) other anti-thyroid therapies used in Graves/TED also see similar increases in LDL, which end up being transient. We think IMVT-1401, in a way, is replicating this mechanism. While we will need to see additional data from the company to confirm, the stock is down -50% in the pre-market and we don't think this program is dead."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: UBS Upgrades Terex (TEX) to Buy
- Wizz Air Holdings Plc (WIZZ:LN) (WZZZY) PT Lowered to GBP56 at Deutsche Bank
- Ultra Tech Cement Ltd (UTCEM:IN) PT Raised to INR7,650 at Nomura/Instinet
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Hot Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!